Yehuda E. Deutsch

485 total citations
23 papers, 242 citations indexed

About

Yehuda E. Deutsch is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Yehuda E. Deutsch has authored 23 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 8 papers in Oncology and 7 papers in Genetics. Recurrent topics in Yehuda E. Deutsch's work include Acute Myeloid Leukemia Research (15 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Yehuda E. Deutsch is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Yehuda E. Deutsch collaborates with scholars based in United States, Canada and Mexico. Yehuda E. Deutsch's co-authors include Eckhard R. Podack, Joseph D. Rosenblatt, Tamar Tadmor, Stefan Glück, Judith Hurley, J. Slingerland, Alberto J. Montero, Eli Avisar, Catherine F. Welsh and Leonidas G. Koniaris and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Yehuda E. Deutsch

23 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yehuda E. Deutsch United States 8 103 72 57 52 44 23 242
Stefania Crisci Italy 11 88 0.9× 139 1.9× 53 0.9× 34 0.7× 59 1.3× 27 322
Ewa Paszkiewicz‐Kozik Poland 10 164 1.6× 93 1.3× 17 0.3× 97 1.9× 148 3.4× 57 316
G. Laurent France 11 59 0.6× 120 1.7× 122 2.1× 35 0.7× 53 1.2× 17 349
Sichu Liu China 11 78 0.8× 61 0.8× 40 0.7× 67 1.3× 93 2.1× 25 251
Meagan S. Barbee United States 6 232 2.3× 71 1.0× 25 0.4× 82 1.6× 22 0.5× 8 331
Nebojša Manojlović Serbia 8 215 2.1× 58 0.8× 25 0.4× 22 0.4× 43 1.0× 25 277
Millie Wang United Kingdom 7 38 0.4× 34 0.5× 42 0.7× 74 1.4× 23 0.5× 11 269
Adam Walter‐Croneck Poland 10 130 1.3× 110 1.5× 174 3.1× 39 0.8× 25 0.6× 32 276
Abhijeet Kumar United States 9 166 1.6× 70 1.0× 43 0.8× 59 1.1× 105 2.4× 38 352
Friederike Braulke Germany 10 57 0.6× 66 0.9× 190 3.3× 32 0.6× 32 0.7× 31 305

Countries citing papers authored by Yehuda E. Deutsch

Since Specialization
Citations

This map shows the geographic impact of Yehuda E. Deutsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yehuda E. Deutsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yehuda E. Deutsch more than expected).

Fields of papers citing papers by Yehuda E. Deutsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yehuda E. Deutsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yehuda E. Deutsch. The network helps show where Yehuda E. Deutsch may publish in the future.

Co-authorship network of co-authors of Yehuda E. Deutsch

This figure shows the co-authorship network connecting the top 25 collaborators of Yehuda E. Deutsch. A scholar is included among the top collaborators of Yehuda E. Deutsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yehuda E. Deutsch. Yehuda E. Deutsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Dasom, Akriti Jain, Yehuda E. Deutsch, et al.. (2022). CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 22(10). 774–779. 8 indexed citations
2.
Ball, Somedeb, Todd C. Knepper, Yehuda E. Deutsch, et al.. (2022). Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 128(21). 3880–3887. 10 indexed citations
3.
Chan, Onyee, Najla Al Ali, Somedeb Ball, et al.. (2022). The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes. Blood. 140(Supplement 1). 3435–3437. 1 indexed citations
4.
Andorsky, David, Sarah Tomassetti, Yehuda E. Deutsch, et al.. (2021). Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations. Blood. 138(Supplement 1). 3599–3599. 1 indexed citations
5.
Ball, Somedeb, Todd C. Knepper, Yehuda E. Deutsch, et al.. (2021). Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.. Journal of Clinical Oncology. 39(15_suppl). 7024–7024. 1 indexed citations
6.
Rahman, Zaid Abdel, Jan Philipp Bewersdorf, Amer M. Zeidan, et al.. (2020). Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. Blood. 136(Supplement 1). 5–7. 1 indexed citations
7.
Stover, Angela M., Benjamin Y. Urick, Allison M. Deal, et al.. (2019). ON5 DEVELOPMENT AND TESTING OF PATIENT-REPORTED OUTCOME PERFORMANCE MEASURES (PRO-PMS) FOR COMPARING ONCOLOGY PRACTICES. Value in Health. 22. S413–S413. 1 indexed citations
8.
Sandoval‐Sus, Jose, et al.. (2019). Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab. Clinical Lymphoma Myeloma & Leukemia. 20(3). e113–e117. 1 indexed citations
9.
Stover, Angela M., Allison M. Deal, Jennifer Jansen, et al.. (2019). Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice.. Journal of Clinical Oncology. 37(27_suppl). 173–173. 1 indexed citations
10.
Lee, Dasom, Yehuda E. Deutsch, Onyee Chan, et al.. (2019). Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia. Blood. 134(Supplement_1). 3895–3895. 2 indexed citations
11.
Lee, Dasom, Yehuda E. Deutsch, Onyee Chan, et al.. (2019). Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax. Blood. 134(Supplement_1). 1357–1357. 7 indexed citations
12.
Deutsch, Yehuda E., Jose Sandoval‐Sus, Terrence Bradley, et al.. (2019). Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation. Blood. 134(Supplement_1). 3896–3896. 3 indexed citations
13.
14.
Knepper, Todd C., Yehuda E. Deutsch, Justin M. Watts, et al.. (2018). Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia. Blood. 132(Supplement 1). 1524–1524. 2 indexed citations
15.
Talati, Chetasi, Aaron D. Goldberg, Pinkal Desai, et al.. (2018). Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia. Blood. 132(Supplement 1). 2741–2741. 5 indexed citations
16.
Berebichez‐Fridman, Roberto, et al.. (2016). Stewart-Treves Syndrome: A Case Report and Review of the Literature. Case Reports in Oncology. 9(1). 205–211. 24 indexed citations
17.
Campuzano‐Zuluaga, Germán, Yehuda E. Deutsch, Matthew Salzberg, et al.. (2015). Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?. American Journal of Hematology. 91(3). 277–282. 8 indexed citations
18.
Deutsch, Yehuda E., Germán Campuzano‐Zuluaga, Matthew Salzberg, et al.. (2014). Clinical Utility of Morphological Evaluation of Day 14 Bone Marrow Biopsies in Acute Myeloid Leukemia Patients Undergoing Standard Induction Chemotherapy: Time to Change Practice?. Blood. 124(21). 1004–1004. 4 indexed citations
19.
Deutsch, Yehuda E., Tamar Tadmor, Eckhard R. Podack, & Joseph D. Rosenblatt. (2011). CD30: an important new target in hematologic malignancies. Leukemia & lymphoma. 52(9). 1641–1654. 59 indexed citations
20.
Montero, Alberto J., C. Marcela Díaz‐Montero, Yehuda E. Deutsch, et al.. (2011). Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer. Breast Cancer Research and Treatment. 132(1). 215–223. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefania Crisci Breakdown of academic impact, for papers by Ewa Paszkiewicz‐Kozik Breakdown of academic impact, for papers by G. Laurent Breakdown of academic impact, for papers by Sichu Liu Breakdown of academic impact, for papers by Meagan S. Barbee Breakdown of academic impact, for papers by Nebojša Manojlović Breakdown of academic impact, for papers by Millie Wang Breakdown of academic impact, for papers by Adam Walter‐Croneck Breakdown of academic impact, for papers by Abhijeet Kumar Breakdown of academic impact, for papers by Friederike Braulke
Rankless by CCL
2026